Summary:
New Delhi: Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, today announced that it will introduce a 400 mg version of oral antiviral FabiFlu®, for the treatment of mild to moderate COVID-19 in India. The higher strength will improve patient compliance and experience, by effectively reducing the number of tablets that patients require per day. A higher pill burden has been associated with lower adherence to therapy, the latter affecting viral suppression and overall treatment outcomes. The 400 mg version is a result of Glenmark's own R&D efforts to improve treatment experience for patients in India,” she added. The combination study which is called the FAITH trial is looking to enrol 158 hospitalized patients of moderate COVID-19 in India..